Lilly completes acquisition of Adverum and its wet AMD gene therapy Ixo-vec
Lilly's purchase of an eye gene therapy company does not change any GLP-1 medication, but it shows where the maker of diabetes and obesity drugs is putting research money.
Eli Lilly and Company announced on Oct. 24, 2025 that it had a definitive agreement to acquire Adverum Biotechnologies, a clinical-stage company developing gene therapies for eye disease, and the deal closed on Dec. 9, 2025 after a tender offer [1][2]. The purchase adds Ixo-vec, an experimental one-time treatment for wet age-related macular degeneration (wet AMD), to Lilly's pipeline [1].
Under the merger agreement, Lilly paid $3.56 per Adverum share in cash at closing, plus one non-transferrable contingent value right (CVR) per share [1]. Each CVR can pay up to $8.91 more in cash if two milestones are met, for total potential consideration of up to $12.47 per share [1]. The total value of the acquisition was not disclosed [1].
The CVR pays up to $1.78 per CVR if the U.S. Food and Drug Administration approves Ixo-vec before the seventh anniversary of closing, and up to $7.13 per CVR the first time annual worldwide net sales of Ixo-vec exceed $1.0 billion before the tenth anniversary of closing [1].
Alongside the deal, Adverum signed a promissory note with Lilly secured by all of Adverum's assets, including its intellectual property rights, allowing Adverum to borrow up to $65 million in four installments to support Ixo-vec trials and development before closing [1]. Without that funding, Adverum's remaining cash and cash equivalents were expected to finance only its October 2025 operations and wind-down activities, according to the announcement [1].
The tender offer expired at one minute past 11:59 p.m. Eastern Time on Dec. 8, 2025 [2]. Computershare, acting as depositary and paying agent, advised Lilly that 16,493,335 shares — about 64% of the issued and outstanding shares at that time — were validly tendered and not validly withdrawn, and all conditions to the offer were satisfied [2]. The parties said they expected to complete the acquisition on Dec. 9, 2025 [2].
Ixo-vec, also called ixoberogene soroparvovec and formerly ADVM-022, is designed to be given as a single intravitreal injection in a physician's office, delivering continuous levels of aflibercept [1]. It is being evaluated in the Phase 3 ARTEMIS trial, which had completed screening as of the October announcement [1]. The FDA granted the program Fast Track and Regenerative Medicine Advanced Therapy designations, the European Medicines Agency granted PRIME designation, and the UK's Medicines and Healthcare Products Regulatory Agency gave it an Innovation Passport [1].
"Ixo-vec has the potential to transform wAMD treatment from a paradigm of chronic care with repeated intravitreal injections to a convenient one-time therapy," said Andrew Adams, Lilly group vice president, Molecule Discovery [1]. Laurent Fischer, Adverum's president and chief executive officer, said the combination could accelerate "a transformative One and Done therapy that can potentially restore and preserve vision for millions of patients living with wAMD" [1]. Adverum's board unanimously approved the transaction after reviewing strategic alternatives, including discussions with other potential partners and buyers [1].
Why it matters for patients
No GLP-1 medication is involved in this transaction. Lilly is described in the announcement as working across diabetes care, obesity and its long-term effects, Alzheimer's disease, immune disorders and cancer, as well as genetic medicine [1]. The Adverum purchase is an eye-disease gene therapy deal, so it does not change the availability, price or coverage of semaglutide, tirzepatide or any other GLP-1 drug today.
The condition involved, wet AMD, is described as a serious, chronic and progressive retinal disease affecting millions of people worldwide, and current anti-VEGF treatment involves repeated injections into the eye [1]. A one-time treatment, if it works and is approved, could reduce that burden. Ixo-vec has not been approved by the FDA, and results from the Phase 3 ARTEMIS trial have not been reported [1].
The CVR structure means part of the payout to Adverum shareholders depends on future events — an FDA approval and a $1.0 billion sales threshold — and Lilly has stated there can be no guarantee that all or any of the contingent consideration will become payable [1][2].
What happens next
The acquisition was expected to be consummated on Dec. 9, 2025 under the merger agreement dated Oct. 24, 2025 [2]. The CVR approval milestone runs until the seventh anniversary of closing, and the sales milestone until the tenth anniversary of closing; both are measured from the closing date, which was not stated precisely beyond Dec. 9, 2025 [1][2]. The timing of Phase 3 data from ARTEMIS has not been disclosed [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.